Innate Pharma's Four Abstracts With Innate's Drug Candidates Accepted For The European Association Of Hematology 2024 Congress
Innate Pharma's Four Abstracts With Innate's Drug Candidates Accepted For The European Association Of Hematology 2024 Congress
Innate Pharma 關於Innate候選藥物的四份摘要獲得 2024 年歐洲血液學協會大會的批准
- Two abstracts on SAR443579 (IPH6101), ANKET platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under development by partner Sanofi in blood cancer
- Two abstracts on IPH6501, Innate's second generation ANKET for the treatment of relapsed or refractory CD20-expressing B-cell Non-Hodgkin's Lymphomas
- 兩份關於ANKET平台主要資產 SAR443579（IPH6101）的摘要，這是合作伙伴賽諾菲正在開發的用於血癌的三功能抗CD123 nkp46xCD16 NK細胞參與器
- 兩份關於 IPH6501 的摘要，這是 Innate 的第二代 ANKET，用於治療復發或難治性表達 CD20 的 B 細胞非霍奇金淋巴瘤
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。